Global Oncolytic Virus Therapy market is estimated to reach $138.29 million in 2019 with a CAGR of 26.3% from 2019 to 2026.
Table of Content 1. Market Introduction 1.1. Executive Summary 1.2. Market Definition 1.3. Market Scope 2. Research Methodology 2.1. Primary Research 2.2. Research Methodology 2.3. Assumptions & Exclusions 2.4. Secondary data sources 3. Oncolytic Virus Therapy Market Overview 3.1. Report Segmentation & Scope 3.2. Key Market Trend 3.3. Drivers 3.3.1. Rising prevalence rate of cancer globally 3.3.2. Side effects associated with conventional cancer therapies such as Chemotherapy and radiation therapy 3.3.3. undefined 3.4. Restraints 3.4.1. Cannot destroy resistant cancer cells 3.4.2. Limited replication and spreading 3.4.3. Antiviral immune responses 3.4.4. These therapies are still at its initial stage 3.5. Opportunities 3.5.1. On-going R&D activities to get a perfect cure by these therapies 3.5.2. Numerous government investments and initiatives 3.6. Porter’s Five Forces Analysis 3.6.1. Porter’s Five Forces Analysis 3.7. Market Share Analysis 4. Type Overview 4.1. Introduction 4.1.1. Market Size & Forecast 4.2. Newcastle Disease Virus-Based Oncolytic Viruses 4.2.1. Market Size & Forecast 4.3. Vaccinia Virus-Based Oncolytic Viruses 4.3.1. Market Size & Forecast 4.4. Vesicular Stomatitis Virus-Based Oncolytic Viruses 4.4.1. Market Size & Forecast 4.5. Adenoviruses-Based Oncolytic Viruses 4.5.1. Market Size & Forecast 4.6. HSV-Based Oncolytic Viruses 4.6.1. Market Size & Forecast 5. Application Overview 5.1. Introduction 5.1.1. Market Size & Forecast 5.2. Breast cancer 5.2.1. Market Size & Forecast 5.3. Ovarian cancer 5.3.1. Market Size & Forecast 5.4. Melanoma 5.4.1. Market Size & Forecast 5.5. Prostate cancer 5.5.1. Market Size & Forecast 5.6. Others 5.6.1. Market Size & Forecast 6. Oncolytic Virus Therapy Market Regional Overview 6.1. Introduction 6.1.1. Market Size & Forecast 6.2. North America Oncolytic Virus Therapy Market 6.2.1. North America Market Size & Forecast, By Country 6.2.2. North America Market Size & Forecast, By Type 6.2.3. North America Market Size & Forecast, By Application 6.2.4. U.S. 6.2.4.1. Market Size and Forecast 6.2.5. Canada 6.2.5.1. Market Size and Forecast 6.2.6. Mexico 6.2.6.1. Market Size and Forecast 6.3. Europe Oncolytic Virus Therapy Market 6.3.1. Europe Market Size & Forecast, By Country 6.3.2. Europe Market Size & Forecast, By Type 6.3.3. Europe Market Size & Forecast, By Application 6.3.4. Germany 6.3.4.1. Market Size and Forecast 6.3.5. France 6.3.5.1. Market Size and Forecast 6.3.6. UK 6.3.6.1. Market Size and Forecast 6.3.7. Italy 6.3.7.1. Market Size and Forecast 6.3.8. Spain 6.3.8.1. Market Size and Forecast 6.3.9. Rest of Europe 6.3.9.1. Market Size and Forecast 6.4. Asia-Pacific Oncolytic Virus Therapy Market 6.4.1. Asia-Pacific Market Size & Forecast, By Country 6.4.2. Asia-Pacific Market Size & Forecast, By Type 6.4.3. Asia-Pacific Market Size & Forecast, By Application 6.4.4. Japan 6.4.4.1. Market Size and Forecast 6.4.5. China 6.4.5.1. Market Size and Forecast 6.4.6. Australia 6.4.6.1. Market Size and Forecast 6.4.7. India 6.4.7.1. Market Size and Forecast 6.4.8. South Korea 6.4.8.1. Market Size and Forecast 6.4.9. Rest of Asia-Pacific 6.4.9.1. Market Size and Forecast 6.5. South America Oncolytic Virus Therapy Market 6.5.1. South America Market Size & Forecast, By Country 6.5.2. South America Market Size & Forecast, By Type 6.5.3. South America Market Size & Forecast, By Application 6.5.4. Brazil 6.5.4.1. Market Size and Forecast 6.5.5. Argentina 6.5.5.1. Market Size and Forecast 6.5.6. Rest of South America 6.5.6.1. Market Size and Forecast 6.6. Middle East & Africa Oncolytic Virus Therapy Market 6.6.1. Middle East & Africa Market Size & Forecast, By Country 6.6.2. Middle East & Africa Market Size & Forecast, By Type 6.6.3. Middle East & Africa Market Size & Forecast, By Application 6.6.4. GCC Countries 6.6.4.1. Market Size and Forecast 6.6.5. Egypt 6.6.5.1. Market Size and Forecast 6.6.6. South Africa 6.6.6.1. Market Size and Forecast 6.6.7. Rest of Middle East & Africa 6.6.7.1. Market Size and Forecast 7. Company Profile 7.1. Biovex 7.1.1. Company Basic Information, Manufacturing Base, Sales Area and Its Competitors 7.1.2. Biovex Product Category, Application, and Specification 7.1.3. Biovex Financial Performance (2016-2018) 7.1.4. Main Business/Business Overview 7.2. Cell Genesys 7.3. Cold Genesys 7.4. Crusade Laboratories 7.5. Genelux Corporation 7.6. Lokon Pharma 7.7. Merck 7.8. MultiVir 7.9. PsiOxus Therapeutics 7.10. SillaJen Biotherapeutics 7.11. Sorrento Therapeutics 7.12. TILT Biotherapeutics 7.13. Vyriad